Amicogen KRX:092040KOSDAQ
아미코젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Amicogen reported revenue of ₩13.4bn, up 32.0% year on year, and an operating loss of ₩1.3bn. Amicogen (아미코젠) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% 4 quarters of losses Screener
Amicogen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩13.4bn | +32.0% | −₩1.3bn | −₩20.8bn |
| Q1 2026 | ₩12.3bn | +13.5% | −₩3.2bn | ₩19.4bn |
| Q4 2025 derived | ₩10.9bn | -80.9% | −₩3.9bn | −₩5.5bn |
| Q3 2025 | ₩10.1bn | -74.6% | −₩4.7bn | −₩13.0bn |
| Q2 2025 | ₩10.1bn | -76.2% | −₩4.2bn | −₩6.0bn |
| Q1 2025 | ₩10.8bn | -68.3% | −₩4.3bn | −₩5.8bn |
| Q4 2024 derived | ₩56.9bn | +45.8% | −₩802m | −₩38.7bn |
| Q3 2024 | ₩39.9bn | -7.5% | −₩1.4bn | ₩2.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Amicogen top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Amicogen news Korean headlines
No articles yet.